Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536575 | 0.84 | ESR1 (0.41) | ESR1TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL1355116 | 0.83 | MMP2 (0.37) | TSHRMAPK1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2533540 | 0.79 | ESR1 (0.38) | ESR1TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL4554082 | 0.79 | TSHR (0.56) | ESR1TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL687367 | 0.78 | ESR1 (0.37) | ESR1TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL9145353 | 0.78 | SMN1; SMN2 (0.37) | ESR1TSHRMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL12407129 | 0.78 | KEAP1 (0.50) | ESR1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6640412 | 0.78 | TSHR (0.54) | ESR1TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL18346856 | 0.76 | PER2 (0.47) | ESR1TSHRMAPK1HSD17B10KMT2A | |
| SCHEMBL9464190 | 0.76 | ESR1 (0.44) | ESR1TSHRMAPK1HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20230120169-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2023-04-20 | — | — | US | disclosed |
| US-11612599-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2023-03-28 | — | — | US | disclosed |
| US-11591327-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2023-02-28 | — | — | US | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| EP-2260044-A2 | THIENOPYRIMIDINES | Merck Patent GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2197886-A1 | 5-CYANO-THIENOPYRIDINES FOR THE TREATMENT OF TUMORS | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009124653-A2 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| WO-2009049743-A1 | 5-CYANO-THIENOPYRIDINES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-5470985-A | Dye for optical recording media, photostability | KONICA CORPORATION (JP) | 1995-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612599-B2 | Glycosidase inhibitors | ENGASE, GAA, GLA | ESR1 3718/4885TSHR 3591/4885MAPK1 3843/4885 |
| US-20230120169-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | DNPEP, GAA, SLC30A5 | ESR1 4405/4885TSHR 4619/4885MAPK1 3288/4885 |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | ESR1 4588/4885TSHR 3993/4885MAPK1 3972/4885 |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | ESR1 3728/4885TSHR 2652/4885MAPK1 4229/4885 |
| US-11591327-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | ESR1 4405/4885TSHR 4619/4885MAPK1 3288/4885 |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | ESR1 3630/4885TSHR 2808/4885MAPK1 3627/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | ESR1 985/4885TSHR 226/4885MAPK1 1283/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | ESR1 602/4885TSHR 223/4885MAPK1 2500/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | ESR1 1249/4885TSHR 3393/4885MAPK1 4227/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | ESR1 1309/4885TSHR 1062/4885MAPK1 4263/4885 |
| US-20100234369-A1 | 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS | TGFBR1, TGFBR2, ACVR1 | ESR1 3261/4885TSHR 308/4885MAPK1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.